U.S. patent application number 14/150674 was filed with the patent office on 2014-11-13 for humanized monoclonal antibodies to hepatocyte growth factor.
This patent application is currently assigned to Galaxy Biotech, LLC. The applicant listed for this patent is Galaxy Biotech, LLC. Invention is credited to Kyung Jin Kim, Hangil Park, Maximiliano Vasquez, Lihong Wang.
Application Number | 20140335076 14/150674 |
Document ID | / |
Family ID | 38564195 |
Filed Date | 2014-11-13 |
United States Patent
Application |
20140335076 |
Kind Code |
A1 |
Kim; Kyung Jin ; et
al. |
November 13, 2014 |
Humanized Monoclonal Antibodies to Hepatocyte Growth Factor
Abstract
The present invention is directed toward a humanized
neutralizing monoclonal antibody to hepatocyte growth factor, a
pharmaceutical composition comprising same, and methods of
treatment comprising administering such a pharmaceutical
composition to a patient.
Inventors: |
Kim; Kyung Jin; (Cupertino,
CA) ; Park; Hangil; (San Francisco, CA) ;
Wang; Lihong; (Palo Alto, CA) ; Vasquez;
Maximiliano; (Palo Alto, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Galaxy Biotech, LLC |
Sunnyvale |
CA |
US |
|
|
Assignee: |
Galaxy Biotech, LLC
Sunnyvale
CA
|
Family ID: |
38564195 |
Appl. No.: |
14/150674 |
Filed: |
January 8, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12569463 |
Sep 29, 2009 |
8628778 |
|
|
14150674 |
|
|
|
|
11731774 |
Mar 29, 2007 |
7632926 |
|
|
12569463 |
|
|
|
|
60788243 |
Apr 1, 2006 |
|
|
|
Current U.S.
Class: |
424/133.1 |
Current CPC
Class: |
C07K 2317/73 20130101;
A61K 2039/505 20130101; C07K 2317/24 20130101; C07K 16/22 20130101;
C07K 2317/76 20130101; A61P 35/00 20180101 |
Class at
Publication: |
424/133.1 |
International
Class: |
C07K 16/22 20060101
C07K016/22 |
Goverment Interests
STATEMENT OF GOVERNMENT INTEREST
[0002] The work described in this application was funded in part by
Grant 2R44CA101283-02 from the National Institutes of Health. The
US government may have certain rights in this invention.
Claims
1-29. (canceled)
30. A method of measuring the level of HGF in a tumor, the method
comprising staining a tumor biopsy with a humanized anti-HGF
monoclonal antibody wherein the monoclonal antibody comprises
mature variant light and heavy chain V region sequences that are at
least 90% identical to the respective HuL2G7 mature light and heavy
chain V regions and binds HGF.
31. The method of claim 31 wherein the antibody is labeled.
32. A method of measuring the level of HGF in the circulation of a
patient with a tumor, the method comprising combining serum from
the patient with a humanized anti-HGF monoclonal antibody wherein
the monoclonal antibody comprises mature variant light and heavy
chain V region sequences that are at least 90% identical to the
respective HuL2G7 mature light and heavy chain V regions and binds
HGF.
33. The method of claim 32 wherein the antibody is labeled.
34. A kit for measuring HGF in a patient sample, comprising a
fluorescently labeled humanized anti-HGF monoclonal antibody
wherein the monoclonal antibody comprises mature variant light and
heavy chain V region sequences that are at least 90% identical to
the respective HuL2G7 mature light and heavy chain V regions and
binds HGF.
35. A method of purifying HGF by affinity chromatography, the
method comprising combining a sample containing HGF to immobilized
humanized anti-HGF monoclonal antibody under conditions in which
the HGF is specifically bound by the antibody, removing unbound
material, and recovering the bound HGF, wherein the monoclonal
antibody comprises mature variant light and heavy chain V region
sequences that are at least 90% identical to the respective HuL2G7
mature light and heavy chain V regions and binds HGF.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The present application is a nonprovisional of U.S. Ser. No.
60/788,243 filed Apr. 1, 2006, which is incorporated by reference
in its entirety for all purposes.
FIELD OF THE INVENTION
[0003] The present invention relates generally to the combination
of monoclonal antibody (mAb) and recombinant DNA technologies for
developing novel biologics, and more particularly, for example, to
the production of humanized monoclonal antibodies that bind to and
neutralize Hepatocyte Growth Factor.
BACKGROUND OF THE INVENTION
[0004] Human Hepatocyte Growth Factor (HGF) is a multifunctional
heterodimeric polypeptide produced by mesenchymal cells. HGF has
been shown to stimulate angiogenesis, morphogenesis and
motogenesis, as well as the growth and scattering of various cell
types (Bussolino et al., J. Cell. Biol. 119: 629, 1992; Zarnegar
and Michalopoulos, J. Cell. Biol. 129:1177, 1995; Matsumoto et al.,
Ciba. Found. Symp. 212:198, 1997; Birchmeier and Gherardi, Trends
Cell. Biol. 8:404, 1998; Xin et al. Am. J. Pathol. 158:1111, 2001).
The pleiotropic activities of HGF are mediated through its
receptor, a transmembrane tyrosine kinase encoded by the
proto-oncogene cMet. In addition to regulating a variety of normal
cellular functions, HGF and its receptor c-Met have been shown to
be involved in the initiation, invasion and metastasis of tumors
(Jeffers et al., J. Mol. Med. 74:505, 1996; Comoglio and Trusolino,
J. Clin. Invest. 109:857, 2002). HGF/cMet are coexpressed, often
over-expressed, on various human solid tumors including tumors
derived from lung, colon, rectum, stomach, kidney, ovary, skin,
multiple myeloma and thyroid tissue (Prat et al., Int. J. Cancer
49:323, 1991; Chan et al., Oncogene 2:593, 1988; Weidner et al.,
Am. J. Respir. Cell. Mol. Biol. 8:229, 1993; Derksen et al., Blood
99:1405, 2002). HGF acts as an autocrine (Rong et al., Proc. Natl.
Acad. Sci. USA 91:4731, 1994; Koochekpour et al., Cancer Res.
57:5391, 1997) and paracrine growth factor (Weidner et al., Am. J.
Respir. Cell. Mol. Biol. 8:229, 1993) and anti-apoptotic regulator
(Gao et al., J. Biol. Chem. 276:47257, 2001) for these tumors.
[0005] HGF is a 102 kDa protein with sequence and structural
similarity to plasminogen and other enzymes of blood coagulation
(Nakamura et al., Nature 342:440, 1989; Weidner et al., Am. J.
Respir. Cell. Mol. Biol. 8:229, 1993). Human HGF is synthesized as
a 728 amino acid precursor (preproHGF), which undergoes
intracellular cleavage to an inactive, single chain form (proHGF)
(Nakamura et al., Nature 342:440, 1989; Rosen et al., J. Cell.
Biol. 127:1783, 1994). Upon extracellular secretion, proHGF is
cleaved to yield the biologically active disulfide-linked
heterodimeric molecule composed of an .alpha.-subunit and
.beta.-subunit (Nakamura et al., Nature 342:440, 1989; Naldini et
al., EMBO J. 11:4825, 1992). The .alpha.-subunit contains 440
residues (69 kDa with glycosylation), consisting of the N-terminal
hairpin domain and four kringle domains. The .beta.-subunit
contains 234 residues (34 kDa) and has a serine protease-like
domain, which lacks proteolytic activity. HGF has two unique cell
specific binding sites: a high affinity (Kd=2.times.10.sup.-10 M)
binding site for the cMet receptor and a low affinity (Kd=10.sup.-9
M) binding site for heparin sulfate proteoglycans (HSPG), which are
present on the cell surface and extracellular matrix (Naldini et
al., Oncogene 6:501, 1991; Bardelli et al., J. Biotechnol. 37:109,
1994; Sakata et al., J. Biol. Chem., 272:9457, 1997).
[0006] The cMet receptor is a member of the class IV protein
tyrosine kinase receptor family. The full length cMet gene was
cloned and identified as the cMet proto-oncogene (Cooper et al.,
Nature 311:29, 1984; Park et al., Proc. Natl. Acad. Sci. USA
84:6379, 1987). NK2 (a protein encompassing the N-terminus and
first two kringle domains of the .alpha.-subunit) is sufficient for
binding to cMet and activation of the signal cascade for motility,
however the full length protein is required for the mitogenic
response (Weidner et al., Am. J. Respir. Cell. Mol. Biol. 8:229,
1993). HSPG binds to HGF by interacting with the N terminus of
HGF.
[0007] HGF/cMet have been reported to play important roles in
several aspects of cancer development such as tumor initiation,
invasion, metastasis, regulation of apoptosis and angiogenesis.
Several different approaches have been investigated to obtain an
effective antagonistic molecule: truncated HGF proteins such as NK1
(N terminal domain plus kringle domain 1; Lokker et al., J. Biol.
Chem. 268:17145, 1993), NK2 (N terminal domain plus kringle domains
1 and 2; Chan et al., Science 254:1382, 1991) and NK4 (N-terminal
domain plus four kringle domains; Kuba et al., Cancer Res. 60:6737,
2000), anti-cMet mAbs (Dodge, Master's Thesis, San Francisco State
University, 1998) and anti-HGF mAbs (Cao et al., Proc. Natl. Acad.
Sci. USA 98:7443, 2001, which is incorporated herein by
reference).
[0008] NK1 and NK2 can compete effectively with the binding of HGF
to its receptor, but have been reported to have partial agonistic
activities in vitro (Cioce et al., J. Biol. Chem. 271:13110, 1996;
Schwan et al., J. Cell Biol. 133:709, 1996), rather than purely
antagonist activities as desired. More recently, Kuba et al.,
Cancer Res. 60:6737, 2000, reported that NK4 could partially
inhibit the primary growth and metastasis of murine lung tumor LLC
in a nude mouse model by continuous infusion of NK4. However, the
fact that NK4 had to be administered continuously to obtain a
partial growth inhibition of primary tumors indicates a potentially
short half-life of the NK4 molecule and/or lack of potency.
[0009] Cao et al., Proc. Natl. Acad. Sci. USA 98:7443, 2001,
reported that the administration of a cocktail of three anti-HGF
mAbs, which were selected based upon their ability to inhibit the
scattering activity of HGF in vitro, were able to inhibit the
growth of human tumors in the xenograft nude mouse model. They
postulated that three mAbs recognizing three different binding
sites on HGF were required to inhibit the bioactivities of HGF in
vivo: two mAbs inhibited the binding of HGF to cMet and one mAb
inhibited the binding of HGF to heparin.
[0010] Recently, human mAbs that individually bind and neutralize
HGF developed using transgenic mouse technology have been reported
(Burgess et al., WO 2005/017107A2 and Burgess et al., Cancer Res
66:1721, 2006, each of which is herein incorporated by reference
for all purposes). However, of these at least the 2.12.1 mAb, which
was apparently the most potent in tumor xenograft models,
nonetheless did not inhibit angiogenesis. A mouse mAb L2G7 has been
developed that neutralizes all tested biological activities of HGF
including angiogenesis (U.S. patent application Ser. No. 10/917,915
filed Aug. 13, 2004, and Kim et al. Olin Cancer Res 12:1292, 2006,
each of which is herein incorporated by reference for all
purposes).
[0011] Thus, there is a need for a humanized monoclonal antibody
that blocks biological activity of HGF in vitro and in vivo. The
present invention fulfills this and other needs.
SUMMARY OF THE CLAIMED INVENTION
[0012] In one embodiment, the invention provides a humanized
neutralizing mAb to human Hepatocyte Growth Factor (HGF). The mAb
inhibits at least one, and preferably several or all biological
activities of HGF including binding to its receptor cMet, induction
of scattering of cells such as Madin-Darby canine kidney cells,
induction of proliferation of Mv 1 Lu mink lunk epithelial cells
and/or hepatocytes and/or HUVEC, and stimulation of angiogenesis. A
preferred humanized anti-HGF mAb inhibits, most preferably
completely inhibits, growth of a human tumor xenograft in a mouse.
In a preferred embodiment, the humanized mAb is a humanized L2G7
mAb. In an especially preferred embodiment, the heavy and light
chain variable regions of the mAb have the sequences shown on the
lines labeled HuL2G7 in FIG. 2A and FIG. 2B respectively, or
sequences that are at least 90% or more identical to them. In
another embodiment, the invention provides a humanized monoclonal
antibody (mAb) that binds and neutralizes human Hepatocyte Growth
Factor (HGF), the humanized antibody comprising humanized heavy and
light chains. The humanized heavy chain comprises CDRs from L2G7
and a human heavy chain variable region framework provided that at
least one position of the human heavy chain variable region
framework selected from the group consisting of H29, H30, H48, H66,
H67, H71, H94 is occupied by the amino acid occupying the
corresponding position in the L2G7 heavy chain. The humanized light
chain comprises CDRs from L2G7 and a human light chain variable
region framework provided that at least one position selected from
the group consisting of L3 and L60 is occupied by the amino acid
occupying the corresponding position in the L2G7 light chain.
[0013] Cell lines producing such humanized antibodies are also
provided. In another embodiment, a pharmaceutical composition
comprising a humanized L2G7 mAb is provided. In a third embodiment,
the pharmaceutical composition is administered to a patient
(typically a human patient) to treat cancer or other disease.
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] FIG. 1. Amino acid sequences of the L2G7 mature heavy chain
(A) and light chain (B) variable regions translated from the cloned
cDNAs. The CDRs are underlined. The Kabat numbering system is
used.
[0015] FIG. 2. Amino acid sequences of the HuL2G7 heavy chain (A)
and light chain (B) mature variable regions are shown aligned with
L2G7 and acceptor V regions. The CDRs are underlined in the L2G7
sequences, and the amino acids substituted with mouse L2G7 amino
acids are underlined in the HuL2G7 sequences, with the initial
amino acid H1E double-underlined. The Kabat numbering system is
used.
[0016] FIG. 3. Amino acid sequences of the entire HuL2G7 heavy
chain (A) and light chain (B). The first amino acids of the mature
heavy and light chains (i.e., after cleavage of the signal
sequences) are double underlined and labeled with the number 1;
these amino acids are also the first amino acids of the mature V
regions. In the heavy chain, the first amino acids of the CH1,
hinge, CH2 and CH3 regions are underlined, and in the light chain,
the first amino acid of the C.sub..kappa. region is underlined.
[0017] FIG. 4. Competitive binding assay of HuL2G7, ChL2G7 and L2G7
for binding to HGF.
[0018] FIG. 5. Relative ability of HuL2G7, ChL2G7 and L2G7 to block
binding of HGF to Met.
[0019] FIG. 6. Relative ability of HuL2G7 and L2G7 to inhibit
HGF-induced proliferation of Mv 1 Lu cells.
[0020] FIG. 7. Effect of treatment with HuL2G7 or L2G7 mAb or PBS
control on growth of U87 subcutaneous xenografts in groups of NIH
III Beige/Nude mice. Arrow indicates when injections began, and
error bars show standard error of the mean (s.e.m). The symbols for
L2G7 and HuL2G7 superimpose and cannot be distinguished in the
figure.
[0021] FIG. 8. Effect of four different dose levels of HuL2G7 on
growth of U87 subcutaneous xenografts in groups of NIH III
Beige/Nude mice. Arrow indicates when injections began, and error
bars show s.e.m.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] The invention provides humanized neutralizing anti-HGF
monoclonal antibodies, pharmaceutical compositions comprising them,
and methods of using them for the treatment of disease.
1. Antibodies
[0023] Antibodies are very large, complex molecules (molecular
weight of .about.150,000 or about 1320 amino acids) with intricate
internal structure. A natural antibody molecule contains two
identical pairs of polypeptide chains, each pair having one light
chain and one heavy chain; hence the fundamental structural unit of
an antibody is a tetramer. Each light chain and heavy chain in turn
consists of two regions: a variable ("V") region involved in
binding the target antigen, and a constant ("C") region that
interacts with other components of the immune system. The light and
heavy chain variable regions fold up together in 3-dimensional
space to form a variable region that binds the antigen (for
example, a receptor on the surface of a cell). Within each light or
heavy chain variable region, there are three short segments
(averaging 10 amino acids in length) called the complementarity
determining regions ("CDRs"). The six CDRs in an antibody variable
domain (three from the light chain and three from the heavy chain)
fold up together in 3-D space to form the actual antibody binding
site which locks onto the target antigen. The position and length
of the CDRs have been precisely defined. See Kabat, E. et al.,
Sequences of Proteins of Immunological Interest, U.S. Department of
Health and Human Services, 1983, 1987, which are herein
incorporated by reference. The part of a variable region not
contained in the CDRs is called the framework, which forms the
environment for the CDRs. In each chain, the three CDRs are
interspersed with four framework sections in this order: FR1, CDR1,
FR2, CDR2, FR3, CDR3, FR4.
[0024] Amino acids from the variable regions of the mature heavy
and light chains of immunoglobulins are designated Hx and Lx
respectively, where x is a number designating the position of an
amino acid according to the scheme of Kabat, op. cit. Kabat lists
many amino acid sequences for antibodies for each subgroup, and
lists the most commonly occurring amino acid for each residue
position in that subgroup to generate a consensus sequence. Kabat
uses a method for assigning a residue number to each amino acid in
a listed sequence, and this method for assigning residue numbers
has become standard in the field. Kabat's scheme is extendible to
other antibodies not included in his compendium by aligning the
antibody in question with one of the consensus sequences in Kabat
by reference to conserved amino acids. The use of the Kabat
numbering system readily identifies amino acids at equivalent
positions in different antibodies. For example, an amino acid at
the L50 position of a human antibody occupies the equivalent
position to an amino acid position L50 of a mouse antibody.
Moreover, any two antibody sequences can be uniquely aligned, for
example to determine percent identity, by using the Kabat numbering
system so that each amino acid in one antibody sequence is aligned
with the amino acid in the other sequence that has the same Kabat
number. After alignment, if a subject antibody region (e.g., the
entire mature variable region of a heavy or light chain) is being
compared with the same region of a reference antibody, the
percentage sequence identity between the subject and reference
antibody regions is the number of positions occupied by the same
amino acid in both the subject and reference antibody region
divided by the total number of aligned positions of the two
regions, with gaps not counted, multiplied by 100 to convert to
percentage.
[0025] A monoclonal antibody (mAb) is a single molecular species of
antibody and therefore does not encompass polyclonal antibodies
produced by injecting an animal (such as a rodent, rabbit or goat)
with an antigen, and extracting serum from the animal. A humanized
antibody is a genetically engineered (monoclonal) antibody in which
the CDRs from a mouse antibody ("donor antibody", which can also be
rat, hamster or other similar species) are grafted onto a human
antibody ("acceptor antibody"). Humanized antibodies can also be
made with less than the complete CDRs from a mouse antibody (e.g.,
Pascal's et al., J. Immunol. 169:3076, 2002). Most commonly the
first heavy chain hypervariable loop H1 as defined by Chothia &
Lesk, J. Mol. Biol. 196:901-917, 1987, from the donor antibody is
also transferred to the humanized antibody. Thus, a humanized
antibody is an antibody having CDRs from a donor antibody and
variable region frameworks and constant regions from human
antibodies. The light and heavy chain acceptor frameworks may be
from the same or different human antibodies and may each be a
composite of two or more human antibody frameworks; or
alternatively may be a consensus sequence of a set of human
frameworks (e.g., a subgroup of human antibodies as defined in
Kabat et al, op. cit.), i.e., a sequence having the most commonly
occurring amino acid in the set at each position. In addition, to
retain high binding affinity, at least one of two additional
structural elements can be employed. See, Queen et al., U.S. Pat.
Nos. 5,530,101 and 5,585,089, each of which is incorporated herein
by reference, which provide detailed instructions for construction
of humanized antibodies.
[0026] In the first structural element, the framework of the heavy
chain variable region of the humanized antibody is chosen to have
high sequence identity (at least 65%) with the framework of the
heavy chain variable region of the donor antibody, by suitably
selecting the acceptor antibody from among the many known human
antibodies. In the second structural element, in constructing the
humanized antibody, selected amino acids in the framework of the
human acceptor antibody (outside the CDRs) are replaced with
corresponding amino acids from the donor antibody, in accordance
with specified rules. Specifically, the amino acids to be replaced
in the framework are generally chosen on the basis of their ability
to interact with the CDRs. For example, the replaced amino acids
can be adjacent to a CDR in the donor antibody sequence or within
4-6 angstroms of a CDR in the humanized antibody as measured in
3-dimensional space.
[0027] On the other hand, since humanized mAbs must originate with
a non-human donor mAb, humanized mAbs do not encompass essentially
human mAbs made by isolating nucleic acids encoding variable
regions from a human and selecting them using phage display methods
(see, e.g., Dower et al., WO91/17271; McCafferty et al.,
WO92/001047; Winter, WO92/20791; and Winter, FEBS Lett. 23:92,
1998) or by using transgenic mice (see, e.g., Lonberg et al.,
WO93/12227; Kucherlapati WO91/10741, and Burgess et al. WO
2005/027107A2).
[0028] The epitope of a mAb is the region of its antigen to which
the mAb binds. Two antibodies bind to the same or overlapping
epitope if each competitively inhibits (blocks) binding of the
other to the antigen. That is, a 1.times., 5.times., 10.times.,
20.times. or 100.times. excess of one antibody inhibits binding of
the other by at least 50% but preferably 75%, 90% or even 99% as
measured in a competitive binding assay (see, e.g., Junghans et
al., Cancer Res. 50:1495, 1990). Alternatively, two antibodies have
the same epitope if all amino acid mutations in the antigen that
reduce or eliminate binding of one antibody reduce or eliminate
binding of the other. Two antibodies have overlapping epitopes if
some amino acid mutations that reduce or eliminate binding of one
antibody reduce or eliminate binding of the other.
2. Humanized Neutralizing Anti-HGF Antibodies
[0029] A monoclonal antibody (mAb) that binds HGF (i.e., an
anti-HGF mAb) is said to neutralize HGF, or be neutralizing, if the
binding partially or completely inhibits one or more biological
activities of HGF (i.e., when the mAb is used as a single agent).
Among the biological properties of HGF that a neutralizing antibody
may inhibit are the ability of HGF to bind to its cMet receptor, to
cause the scattering of certain cell lines such as Madin-Darby
canine kidney (MDCK) cells; to stimulate proliferation of (i.e., be
mitogenic for) certain cells including hepatocytes, Mv 1 Lu mink
lung epithelial cells, and various human tumor cells; or to
stimulate angiogenesis, for example as measured by stimulation of
human umbilical vascular endothelial cell (HUVEC) proliferation or
tube formation or by induction of blood vessels when applied to the
chick embryo chorioallantoic membrane (CAM). Antibodies of the
invention preferably bind to human HGF, i.e., to the protein
encoded by the GenBank sequence with Accession number D90334.
[0030] A humanized neutralizing mAb of the invention at a
concentration of, e.g., 0.01, 0.1, 0.5, 1, 2, 5, 10, 20 or 50
.mu.g/ml will inhibit a biological function of HGF (e.g.,
stimulation of proliferation or scattering) by about at least 50%
but preferably 75%, more preferably by 90% or 95% or even 99%, and
most preferably approximately 100% (essentially completely) as
assayed by methods described under Examples or known in the art.
Typically, the extent of inhibition is measured when the amount of
HGF used is just sufficient to fully stimulate the biological
activity, or is 0.01, 0.02, 0.05, 0.1, 0.5, 1, 3 or 10 .mu.g/ml.
Preferably, at least 25%, 50%, 75%, 90%, or 95% or essentially
complete inhibition will be achieved when the molar ratio of
antibody to HGF is 0.1.times., 0.5.times., 1.times., 2.times.,
3.times., 5.times. or 10.times.. Most preferably, the mAb will
neutralize not just one but several of the biological activities
listed above; for purposes herein, an anti-HGF mAb that neutralizes
all the biological activities of HGF will be called "fully
neutralizing", and such mAbs are most preferable. MAbs of the
invention preferably bind specifically to HGF, that is they will
not bind, or only bind to a much lesser extent, proteins that are
related to HGF such as fibroblast growth factor (FGF) and vascular
endothelial growth factor (VEGF). MAbs of the invention typically
have a binding affinity (K.sub.a) for HGF of at least 10.sup.7
M.sup.-1 but preferably 10.sup.8 M.sup.-1 or higher, and most
preferably 10.sup.9 M.sup.-1 or higher or even 10.sup.10 M.sup.-1
or higher.
[0031] Humanized mAbs of the invention include anti-HGF antibodies
in their natural tetrameric form (2 light chains and 2 heavy
chains) and can be of any of the known isotypes IgG, IgA, IgM, IgD
and IgE and their subtypes, i.e., IgG1, IgG2, IgG3, IgG4 and may
comprise a kappa or lambda light chain. The mAbs of the invention
also include fragments of antibodies such as Fv, Fab and
F(ab').sub.2; bifunctional hybrid antibodies (e.g., Lanzavecchia et
al., Eur. J. Immunol. 17:105, 1987), single-chain antibodies
(Huston et al., Proc. Natl. Acad. Sci. USA 85:5879, 1988; Bird et
al., Science 242:423, 1988); and antibodies with altered constant
regions (e.g., U.S. Pat. No. 5,624,821). The source of the CDRs of
the mAb may be of animal (e.g., mouse, rat, hamster or chicken)
origin, or they may be genetically engineered. Rodent mAbs are made
by standard methods well-known in the art, comprising multiple
immunization with HGF in appropriate adjuvant i.p., i.v., or into
the footpad, followed by extraction of spleen or lymph node cells
and fusion with a suitable immortalized cell line, and then
selection for hybridomas that produce antibody binding to HGF.
[0032] The invention provides humanized forms of the mouse L2G7
mAb. The sequences of the mature heavy and light chain variable
regions of the mouse L2G7 mAb are shown in FIGS. 1A and 1B
respectively. Hence, humanized forms of the L2G7 mAb encompass most
or all of the CDR amino acids from these sequences in human
variable region frameworks (including single, composite or
consensus sequence human frameworks). For example, some humanized
antibodies include three intact CDRs from the L2G7 heavy chain and
three intact CDRs from the light chain. Other humanized antibodies
include at least one intact CDR from the L2G7 heavy chain and at
least one intact CDR from the L2G7 light chain. Some humanized
antibodies include at least one CDR in which some residues are from
the corresponding CDR of L2G7 and the others are from a CDR of a
human antibody, preferably the same human antibody as supplies the
variable region framework containing the CDR.
[0033] In some humanized antibodies of the invention at least 1, 3,
5 or all positions selected from the group H29, H30, H48, H66, H67,
H71, H94, L3, and L60 are occupied by an amino acid present at the
corresponding position by Kabat numbering in the mouse L2G7
antibody. In the human acceptor variable region frameworks used in
the Examples, all of these positions are occupied by human residues
differing from the amino acid present at the corresponding position
in the mouse L2G7 antibody. Thus, it is preferable to substitute
all or most positions selected from the group. If other human
variable region frameworks are used, some of the positions may be
occupied by amino acids that are the same in the human variable
region framework and the mouse L2G7 antibody. Accordingly,
substitution is not performed at such positions but can be
performed at other positions differing between the human variable
region framework and mouse L2G7 antibody in accordance with the
rules of Queen, U.S. Pat. No. 5,530,101 and U.S. Pat. No.
5,585,089. Regardless of the choice of human variable region
framework, substitution of other amino acids besides those
specified in the above group is also possible as discussed below.
However, in general neither the heavy chain variable region
framework nor the light chain variable region framework of the
humanized antibody includes more than ten or twelve substitutions
resulting in residues not present in the acceptor human variable
region framework (including human consensus variable region
frameworks and composite human variable region frameworks, as
discussed above.)
[0034] Any constant regions present in the humanized antibodies of
the invention are human or essentially so, having no more than ten,
and preferably two or fewer substitutions relative to a natural
human constant region. Some substitutions are advantageous in
increasing the half-life of an antibody and/or its affinity for
Fc.gamma.Rn, as discussed below. Other substitutions, usually
conservative substitutions, as discussed below, are neutral in
effect.
[0035] Exemplified humanized forms of L2G7 include mature heavy and
light chain variable regions having the sequences shown in FIGS. 2A
and 2B respectively. Other preferred forms of humanized L2G7
include mature heavy and light chain variable regions having
sequences at least 90%, 95%, 98% or 99% identical to these
sequences (when aligned according to Kabat numbering, supra),
and/or differ from them by a small number (typically involving no
more than 5 or 10 amino acids) of functionally inconsequential
substitutions, deletions and/or insertions. For example, the first
amino acid of the heavy chain may be either Glu or Gln. The
substitutions are usually conservative, that is replace an amino
acid with one that is chemically similar. For purposes of
classifying amino acids substitutions as conservative or
nonconservative, amino acids may be grouped as follows: Group I
(hydrophobic sidechains): Met, Ala, Val, Leu, Ile; Group II
(neutral hydrophilic side chains): Cys, Ser, Thr; Group III (acidic
side chains): Asp, Glu; Group IV (basic side chains): Asn, Gln,
His, Lys, Arg; Group V (residues influencing chain orientation):
Gly, Pro; and Group VI (aromatic side chains):Trp, Tyr, Phe.
Conservative substitutions are those that involve substitutions
between amino acids in the same group. Substitutions relative to
the V regions in FIGS. 2A and 2B are preferably avoided at
positions H29, H30, H48, H66, H67, H71, H94, L3, and L60, where
amino acids from mouse L2G7 were included due to the interaction of
these positions with CDRs, as discussed in the Examples.
Substitutions preferably occur in variable region framework
positions, but can also occur in CDR regions. If a CDR region is
substituted, it is preferable to replace a mouse amino acid with an
amino acid from the corresponding position (Kabat numbering) of a
human antibody, preferably the same human antibody that supplies
the acceptor variable region frameworks.
[0036] Usually, the humanized L2G7 mAbs are of the IgG1, IgG2, IgG3
or IgG4 isotype with a kappa light chain. An IgG1 mAb having the
variable regions of FIGS. 2A and 2B respectively combined with
complete human gamma-1 and kappa constant region is designated
HuL2G7. The complete heavy and light chains of HuL2G7 are
respectively shown in FIGS. 3A and 3B. Only the mature parts of
these sequences beginning at the positions indicated by the number
1 actually constitute HuL2G7, as the preceding signal peptides are
cleaved off before or during antibody secretion.
[0037] Variants of HuL2G7 retaining similar binding characteristics
to HuL2G7 can be obtained by mutagenesis followed by mass selection
using the phage display methods discussed above. Variants are
initially selected for specific binding to HGF, optionally in
competition with HuL2G7 or mouse L2G7. Variants having the same or
similar binding characteristics as the exemplified antibody can
then be tested functionally.
[0038] Preferred humanized L2G7 mAbs are neutralizing or fully
neutralizing against HGF as defined supra. Preferably, for some,
most or all biological properties of HGF measured (e.g., binding to
Met, stimulation of proliferation of Mv 1 Lu or HUVEC cells), the
neutralizing activity of the humanized mAb is within 3-fold, more
preferably within 2-fold or 1.5-fold, and most preferably
indistinguishable from (i.e., to within experimental error), the
neutralizing activity of L2G7 itself. That is, no more than 3-fold,
2-fold, 1.5-fold or the same amount of humanized mAb relative to
L2G7 is needed to obtain the same extent of inhibition of the
biological property (for example, as measured by IC50's).
Preferably, the affinity for HGF of the humanized mAbs is also
within 3-fold, 2-fold or essentially indistinguishable from that of
L2G7. Similarly, in xenograft mouse models (e.g., using a human
glioma cell line such as U87), the humanized mAbs preferably
inhibit tumor growth within 3-fold, 2-fold or indistinguishably
from the mouse L2G7 mAb. Indeed, preferably only a 40, 20 or even
10 .mu.g dose of humanized mAb adminstered twice per week
completely inhibits growth of U87 tumor xenografts.
[0039] Humanized mAbs can be expressed by a variety of art-known
methods. For example, genes encoding their light and heavy chain V
regions may first be synthesized from overlapping oligonucleotides
or by PCR mutagenesis of an earlier prepared variant of the desired
gene. Because of the degeneracy of the genetic code, a variety of
DNA sequences encode each antibody amino acid sequence. All DNA
sequences encoding the antibodies described in this application are
expressly included in the invention. However made, the genes
encoding the humanized mAb light and heavy chain genes and inserted
together with C regions into expression vectors (e.g., commercially
available from Invitrogen) that provide the necessary regulatory
regions, e.g., promoters, enhancers, poly A sites, etc. Use of the
CMV promoter-enhancer is preferred. Genes for C regions are now
widely available or may be readily cloned by PCR from human
antibody producing cells. The light and heavy chain genes may be
inserted together into a single vector or into separate vectors.
The expression vectors may then be transfected using various
art-known methods such as lipofection or electroporation into a
variety of mammalian cell lines such as CHO or 293 or non-producing
myelomas including Sp2/0 and NS0, and cells expressing the
antibodies selected by appropriate antibiotic selection. See, e.g.,
U.S. Pat. No. 5,530,101. Larger amounts of antibody may be produced
by growing the cells in commercially available bioreactors.
[0040] Once expressed, the humanized mAbs of the invention may be
purified according to standard procedures of the art such as
microfiltration, ultrafiltration, protein A or G affinity
chromatography, size exclusion chromatography, anion exchange
chromatography, cation exchange chromatography and/or other forms
of affinity chromatography based on organic dyes or the like.
Substantially pure antibodies of at least about 90 or 95%
homogeneity are preferred, and 98% or 99% or more homogeneity most
preferred, for pharmaceutical uses.
3. Therapeutic Methods
[0041] In a preferred embodiment, the present invention provides a
pharmaceutical formulation comprising the humanized antibodies
described herein. Pharmaceutical formulations of the antibodies
contain the mAb in a physiologically acceptable carrier, optionally
with excipients or stabilizers, in the form of lyophilized or
aqueous solutions. Acceptable carriers, excipients or stabilizers
are nontoxic to recipients at the dosages and concentrations
employed, and include buffers such as phosphate, citrate, or
acetate at a pH typically of 5.0 to 8.0, most often 6.0 to 7.0;
salts such as sodium chloride, potassium chloride, etc. to make
isotonic; antioxidants, preservatives, low molecular weight
polypeptides, proteins, hydrophilic polymers such as polysorbate
80, amino acids, carbohydrates, chelating agents, sugars, and other
standard ingredients known to those skilled in the art (See
Remington's Pharmaceutical Science 16.sup.th edition, Osol, A. Ed.
1980). The mAb is typically present at a concentration of 1-100
mg/ml, e.g., 10 mg/ml.
[0042] In another preferred embodiment, the invention provides a
method of treating a patient with a disease using a humanized
anti-HGF mAb such as humanized L2G7, e.g., HuL2G7, in a
pharmaceutical formulation. The mAb prepared in a pharmaceutical
formulation can be administered to a patient by any suitable route,
especially parentally by intravenous infusion or bolus injection,
intramuscularly or subcutaneously. Intravenous infusion can be
given over as little as 15 minutes, but more often for 30 minutes,
or over 1, 2 or even 3 hours. The mAb can also be injected directly
into the site of disease (e.g., a tumor), or encapsulated into
carrying agents such as liposomes. The dose given is sufficient to
alleviate the condition being treated ("therapeutically effective
dose") and is likely to be 0.1 to 5 mg/kg body weight, for example
1, 2, 3 or 4 mg/kg, but may be as high as 10 mg/kg or even 15 or 20
mg/kg. A fixed unit dose may also be given, for example, 50, 100,
200, 500 or 1000 mg, or the dose may be based on the patient's
surface area, e.g., 100 mg/m.sup.2. Usually between 1 and 8 doses,
(e.g., 1, 2, 3, 4, 5, 6, 7 or 8) are administered to treat cancer,
but 10, 20 or more doses may be given. The mAb can be administered
daily, biweekly, weekly, every other week, monthly or at some other
interval, depending, e.g. on the half-life of the mAb, for 1 week,
2 weeks, 4 weeks, 8 weeks, 3-6 months or longer. Repeated courses
of treatment are also possible, as is chronic administration.
[0043] Diseases especially susceptible to therapy with the
humanized anti-HGF mAbs of this invention, e.g., HuL2G7, include
solid tumors believed to require angiogenesis or to be associated
with elevated levels of HGF, for example ovarian cancer, breast
cancer, lung cancer (small cell or non-small cell), colon cancer,
prostate cancer, pancreatic cancer, gastric cancer, liver cancer,
head-and-neck tumors, melanoma and sarcomas of children or adults,
and brain tumors. Indeed, the methods of this invention, especially
systemic treatment with a humanized L2G7 mAb, are especially
applicable to the treatment of brain tumors including meningiomas;
gliomas including ependymomas, oligodendrogliomas, and all types of
astrocytomas (low grade, anaplastic, and glioblastoma multiforme or
simply glioblastoma); medullablastomas, gangliogliomas,
schwannomas, chordomas; and brain tumors primarily of children
including primitive neuroectodermal tumors. Both primary brain
tumors (i.e., arising in the brain) and secondary or metastatic
brain tumors can be treated by the methods of the invention. Other
diseases suitable for treatment by the methods of the invention are
those associated with undesired angiogenesis such as diabetic
retinopathy, age-related macular degeneration, rheumatoid arthritis
and psoriasis.
[0044] In an especially preferred embodiment, the humanized
anti-HGF mAb, e.g., HuL2G7, is administered together with (i.e.,
before, during or after) other anti-cancer therapy. For example,
the mAb may be administered together with any one or more of the
chemotherapeutic drugs known to those of skill in the art of
oncology, for example alkylating agents such as carmustine,
chlorambucil, cisplatin, carboplatin, oxiplatin, procarbazine, and
cyclophosphamide; antimetabolites such as fluorouracil,
floxuridine, fludarabine, gemcitabine, methotrexate and
hydroxyurea; natural products including plant alkaloids and
antibiotics such as bleomycin, doxorubicin, daunorubicin,
idarubicin, etoposide, mitomycin, mitoxantrone, vinblastine,
vincristine, and Taxol (paclitaxel) or related compounds such as
Taxotere.RTM.; agents specifically approved for brain tumors
including temozolomide and Gliadel.RTM. wafer containing
carmustine; and other drugs including irinotecan and Gleevec.RTM.
and all approved and experimental anti-cancer agents listed in WO
2005/017107 A2 (which is herein incorporated by reference). Other
agents with which the humanized anti-HGF mAb can be administered
include biologics such as monoclonal antibodies, including
Herceptin.TM. against the HER2 antigen, Avastin.TM. against VEGF,
or antibodies to the EGF receptor, as well as small molecule
anti-angiogenic or EGF receptor antagonist drugs. In addition, the
humanized anti-HGF mAb can be used together with radiation therapy
or surgery.
[0045] Treatment (e.g., standard chemotherapy) including the
humanized anti-HGF mAb antibody, e.g., HuL2G7, can increase the
median progression-free survival or overall survival time of
patients with these tumors (e.g., ovarian, breast, lung, pancreas,
brain and colon, especially when relapsed or refractory) by at
least 30% or 40% but preferably 50%, 60% to 70% or even 100% or
longer, compared to the same treatment (e.g., chemotherapy) but
without anti-HGF mAb. In addition or alternatively, treatment
(e.g., standard chemotherapy) including the anti-HGF mAb can
increase the complete response rate, partial response rate, or
objective response rate (complete+partial) of patients with these
tumors (e.g., ovarian, breast, lung, pancreas, brain and colon,
especially when relapsed or refractory) by at least 30% or 40% but
preferably 50%, 60% to 70% or even 100% compared to the same
treatment (e.g., chemotherapy) but without the anti-HGF mAb. For
brain tumors such as glioblastomas, treatment with the humanized
anti-HGF mAb, alone or in combination with other agents, preferably
provides a partial, complete or objective response rate of at least
5% or 10%, more preferably 20% or 25% or 30%, and most preferably
40%, 50% or higher.
[0046] Typically, in a clinical trial (e.g., a phase II, phase
II/III or phase III trial), the aforementioned increases in median
progression-free survival and/or response rate of the patients
treated with standard therapy plus the humanized anti-HGF mAb,
e.g., HuL2G7, relative to the control group of patients receiving
standard therapy alone (or plus placebo), are statistically
significant, for example at the p=0.05 or 0.01 or even 0.001 level.
The complete and partial response rates are determined by objective
criteria commonly used in clinical trials for cancer, e.g., as
listed or accepted by the National Cancer Institute and/or Food and
Drug Administration.
4. Other Methods
[0047] The humanized anti-HGF mAbs of the invention also find use
in diagnostic, prognostic and laboratory methods. They may be used
to measure the level of HGF in a tumor or in the circulation of a
patient with a tumor, and therefore to follow and guide treatment
of the tumor. For example, a tumor associated with high levels of
HGF would be especially susceptible to treatment with a humanized
anti-HGF mAb. In particular embodiments, the mAbs can be used in an
ELISA or radioimmunoassay to measure the level of HGF, e.g., in a
tumor biopsy specimen or in serum or in media supernatant of
HGF-secreting cells in cell culture. For various assays, the
anti-HGF mAb may be labeled with fluorescent molecules,
spin-labeled molecules, enzymes or radioisotopes, and may be
provided in the form of kit with all the necessary reagents to
perform the assay for HGF. In other uses, the anti-HGF mAbs are
used to purify HGF, e.g., by affinity chromatography.
EXAMPLES
1. Construction of a Humanized L2G7 Antibody
[0048] The generation of the mouse anti-HGF mAb L2G7, which
neutralizes all tested biological activities of HGF, has already
been described (Kim et al., US20050019327 filed Aug. 13, 2004, and
Kim et al. Clin Cancer Res 12:1292, 2006). The first step to
humanize L2G7 was to clone its light and heavy chain genes, which
was accomplished essentially according to the method of Co et al.,
J. Immunol. 148:1149, 1992. Briefly, RNA was prepared from 10.sup.6
L2G7 (IgG2a, .kappa.) hybridoma cells using an RNeasy Mini Kit
(Qiagen) followed by first strand cDNA synthesis with random
primers using a kit from Stratagene and addition of dG tails with
terminal deoxynucleotidyl transferase (Promega). The heavy and
light chain V regions were respectively amplified from the cDNA
with a primer annealing to the dG tails and a primer annealing to
the N-terminal region of C.sub..gamma.2a for the heavy chain and a
primer annealing to the N-terminal region of C.sub..kappa. for the
light chain, using a high fidelity polymerase AccuPrime Pfx
(Invitrogen). Bands of appropriate sizes were gel purified from the
PCR reactions, and sequenced directly or cloned and then sequenced,
using the dideoxy termination method with an automated sequencer. A
single cDNA sequence was found for the heavy chain, which is shown
after translation in FIG. 1A. Two different apparently non-aberrant
light chain cDNA sequences were found, but amino acid sequencing of
the N-terminus of isolated L2G7 light chain revealed only one of
these chains, the translated amino acid sequence of which is shown
in FIG. 1B.
[0049] To express a chimeric form of L2G7 and later the humanized
mAb, expression vectors similar to the pVk and pVg1 vectors
described in Co et al., J. Immunol. 148:1149, 1992, which contain
the human C.sub..kappa. and C.sub..gamma.1 genes, were constructed
from commercially available vectors and DNA fragments. However, the
light chain vector has the hyg selectable marker instead of gpt,
and the heavy chain vector has the neo selectable marker instead of
Dhfr. The cloned V.sub.L and V.sub.H genes were subcloned into the
appropriate sites of these vectors to generate expression plasmids
for the chimeric L2G7 (chL2G7) mAb light and heavy chain genes. The
chL2G7 mAb was produced and shown to bind HGF as well as L2G7 does,
proving that correct light and heavy chain V regions had been
cloned.
[0050] To design a humanized L2G7 mAb, the methods of Queen et al.,
U.S. Pat. Nos. 5,530,101 and 5,585,089 were generally followed. The
National Center for Biotechnology Information (NCBI) database of
human antibody sequences was scanned, and the human V.sub.H
sequence AAC18323 and V.sub..kappa. sequence BAC01726 were
respectively chosen to serve as acceptor sequences for the L2G7
V.sub.H and V.sub.L sequences because they have particularly high
framework homology (i.e., sequence identity) to them. A computer
program, Deep View Swiss-Pdb Viewer, available on the worldwide web
(http://www.expasy.org/spdbv/), was used to construct a molecular
model of the L2G7 variable domain, which was used to locate the
amino acids in the L2G7 framework that are close enough to the CDRs
to potentially interact with them. To design the humanized L2G7
heavy and light chain variable regions, the CDRs from the mouse
L2G7 mAb were first conceptually grafted into the acceptor
framework regions. At framework positions where the computer model
suggested significant contact with the CDRs, which may be needed to
maintain the CDR conformation, the amino acids from the mouse
antibody were substituted for the original human framework amino
acids. For the humanized L2G7 mAb designated HuL2G7, this was done
at residues 29, 30 (within Chothia hypervariable loop H1), 48, 66,
67, 71 and 94 of the heavy chain and at residues 3 and 60 of the
light chain, using Kabat numbering. In addition, amino acid 1 of
the heavy chain was replaced with E (Glu) because this amino acid
is less likely than Q (Gln) to undergo derivatization in the
antibody protein. The heavy and light chain V region sequences of
HuL2G7 are shown aligned against the respective L2G7 and acceptor V
regions in FIGS. 2A and 2B, with the CDRs and substituted amino
acids highlighted.
[0051] The invention also provides variant humanized L2G7 mAbs
whose mature heavy and light chain variable regions differ from the
sequences of HuL2G7 by a small number (e.g., typically no more than
1, 2, 3, 5 or 10) of replacements, deletions or insertions, usually
in the framework but possibly in the CDRs. In particular, only a
subset of the substitutions described above can be made in the
acceptor frameworks, or additional substitution(s) can be made,
e.g., the mouse L2G7 V.sub.H amino acid 69F may replace the
acceptor amino acid 69M. On the other hand, the V.sub.H amino acid
1E may instead be Q. Indeed, many of the framework residues not in
contact with the CDRs in HuL2G7 can accommodate substitutions of
amino acids from the corresponding positions of L2G7 or other mouse
or human antibodies, and even many potential CDR-contact residues
are also amenable to substitution or even amino acids within the
CDRs.
[0052] Most often the replacements made in the variant humanized
L2G7 sequences are conservative with respect to the replaced HuL2G7
amino acids. Preferably, replacements in HuL2G7 (whether or not
conservative) have no substantial effect on the binding affinity or
potency of the humanized mAb, that is, its ability to neutralize
the biological activities of HGF (e.g., the potency in some or all
of the assays described herein of the variant humanized L2G7 mAb is
essentially the same, i.e., within experimental error, as that of
HuL2G7). Preferably the mature variant light and heavy chain V
region sequences are at least 90%, more preferably at least 95%,
and most preferably at least 98% identical to the respective HuL2G7
mature light and heavy chain V regions. Alternatively, other human
antibody variable regions with high sequence identity to those of
L2G7 are also suitable to provide the humanized antibody framework,
especially kappa V regions from human subgroup I and heavy chain V
regions from human subgroup I, or consensus sequences of these
subgroups.
[0053] The exemplary mAb HuL2G7 discussed in the Examples below has
human .kappa. and .gamma.1 constant regions and is therefore an
IgG1: the complete sequences of the HuL2G7 heavy and light chain
genes including signal peptides are shown in FIG. 3A and FIG. 3B.
(Of course, the signal peptides are cleaved off and are not part of
HuL2G7.) However, it is understood that IgG1 mAbs of other (IgG1,
.kappa.) allotypes are encompassed by the designation HuL2G7.
Humanized mAbs of other isotypes (e.g., IgG2, IgG3 and IgG4) can be
made by combining the HuL2G7 variable regions with the appropriate
human constant regions. Replacements can be made in the HuL2G7
constant regions to reduce or increase effector function such as
complement-mediated cytotoxicity or ADCC (see, e.g., Winter et al.,
U.S. Pat. No. 5,624,821; Tso et al., U.S. Pat. No. 5,834,597; and
Lazar et al., Proc. Natl. Acad. Sci. USA 103:4005, 2006), or to
prolong half-life in humans (see, e.g., Hinton et al., J. Biol.
Chem. 279:6213, 2004). Specifically but without limitation, HuL2G7
having mutations in the IgG constant region to a Gln at position
250 and/or a Leu at position 428 are embodiments of the present
invention.
[0054] Having designed the HuL2G7 mAb, i.e., having chosen the
amino acid sequences of its light and heavy chain V regions (FIG. 2
and FIG. 3), DNA sequences encoding the V regions (including signal
peptides) were routinely chosen via the genetic code; the sequences
began with CTCGAGACCACC before the initiating ATG codon to provide
a restriction site for cloning and a Kozak translation initiation
signal. These genes were synthesized commercially by Genscript
Corp. (Piscataway, N.J.). Alternatively, the method of Co et al.,
J. Immunol. 148:1149, 1992 can be used to synthesize each V region
gene. Briefly, two pairs of overlapping oligonucleotides on
alternating strands are synthesized (Applied Biosystems DNA
synthesizer), which together encompass the entire gene. The
oligonucleotides are 110 to 140 bases long with 15-base overlaps.
Double-stranded DNA fragments are synthesized using Klenow
polymerase from the 5' pair of oligos and separately from the 3'
pair. The 5' DNA fragment is cleaved with the restriction enzymes
cutting at the 5' end and at the center of the V region gene. The
3' DNA fragment is cleaved with the restriction enzymes cutting at
the center and at the 3' end of the V region gene. Each cleaved
fragment is inserted into a suitable cloning vector and transformed
into E. coli, and DNA from a number of isolates is sequenced to
find fragments that have completely correct sequences. For each
gene, a 3-way ligation is then performed to insert the correct 5'
and 3' fragments into the appropriate expression vector to form the
complete gene, the sequence of which is verified.
[0055] To produce the HuL2G7 mAb, human renal epithelial 293-F
cells (Invitrogen) were cultured in FreeStyle 293 expression medium
(FS medium; Invitrogen) and resuspended in FS medium at 10.sup.6
cells/2 ml/macrowell. The HuL2G7 light and heavy chain expression
vector DNAs (1 .mu.g of each) were incubated with 3 .mu.l of Fugene
6 (Roche) in 100 .mu.l FS medium for 30 min at RT; the mixture was
then added to the cells. After 48 hr incubation, transfected cells
were cultured in the presence of 1 mg/ml G418 to select for cells
expressing neo and then spread into 96-well tissue culture plates
(100 .mu.l/well). After approximately 2 weeks, when wells
containing viable cells had become confluent, culture supernatants
from those wells were tested for the presence and quantity of
HuL2G7 by ELISA. Transfected cells may secrete an imbalance of
light and heavy chains, so to ensure that only complete HuL2G7 is
measured, this ELISA uses goat anti-human Fc as a capture agent and
biotinylated anti-human kappa as a detection reagent. The chL2G7
mAb was expressed similarly. Clones of cells expressing relatively
high levels of ChL2G7 and HuL2G7 were respectively expanded and
grown in FS medium. Antibody was purified from culture supernatants
using protein A affinity chromatography and analyzed for purity by
SDS-PAGE.
2. Properties of HuL2G7
[0056] To compare the binding affinity of HuL2G7 with that of
ChL2G7 and L2G7, a competitive binding experiment was performed. A
microtiter plate was coated with 50 .mu.l/well of 2 .mu.g/ml of
goat anti-human IgG-Fc (G.alpha.hIgG-Fc) in PBS overnight at
4.degree. C. and blocked with 2% BSA for 1 hr at RT. After washing,
the plate was incubated with 50 .mu.l/well ChL2G7 mAb (2
.mu.g/well) for 1 hr at RT, followed after washing by 50 .mu.l/well
of human IgG (10 .mu.g/ml) for 1 hr to reduce background. After
washing, wells of the plate were separately incubated for 1 hr with
50 .mu.l/well of various concentrations of purified HuL2G7, ChL2G7
or L2G7 as competitor together with 50 .mu.l/well of HGF-Flag (1
.mu.g/ml). After washing, the plates were then incubated with 50
.mu.l/well of HRP-M2 anti-Flag mAb (Invitrogen) and the bound
HRP-anti-Flag M2 detected by the addition of tetramethylbenzidine
substrate. FIG. 4 shows that HuL2G7, ChL2G7 and L2G7 competed
essentially equally well with the L2G7 bound to the plate for
binding to the soluble HGF-Flag, indicating that these three mAbs
have very similar affinity.
[0057] A key biological activity of HGF is the ability to bind to
its receptor cMet, so the ability of the HuL2G7, ChL2G7 and L2G7
mAbs to inhibit binding of HGF to Met was compared. Met was used in
the form of Met-Fc and HGF in the form of HGF-Flag, which were
prepared as described (U.S. patent application Ser. No. 10/917,915
filed Aug. 13, 2004, and Kim et al. Clin Cancer Res 12:1292, 2006).
A microtiter plate was coated with 50 .mu.l/well of 2 .mu.g/ml each
of two anti-Met mAbs (Galaxy Biotech) in PBS overnight at 4.degree.
C. (alternatively 2 .mu.g/ml G.alpha.hIgG-Fc may be used) and
blocked with 2% BSA for 1 hr at RT. After washing the plates, 50
.mu.l/well of Met-Fc (1 .mu.g/ml) was added to each well for 1 hr
at RT, followed after washing by 50 .mu.l/well of human IgG (10
.mu.g/ml) for 1 hr to reduce background After washing the plates,
50 .mu.l/well of HGF-Flag (0.5 .mu.g/ml) preincubated with various
concentrations of mAbs was added to each well for 1 hr. After
washing, the plates were incubated with 50 .mu.l/well of HRP-M2
anti-Flag mAb (Invitrogen), and the bound HRP-anti-Flag M2 detected
by the addition of the substrate as described above. FIG. 5 shows
that HuL2G7, ChL2G7 and L2G7 blocked binding of HGF to Met equally
well, so these mAbs have very similar activity in this assay.
[0058] Another important biological activity of HGF is the ability
to stimulate proliferation of certain cells, including Mv 1 Lu mink
lung epithelial cells. To compare the ability of HuL2G7 and L2G7 to
neutralize this activity of HGF, Mv 1 Lu cells (2.times.10.sup.4
cells/100 .mu.L/well) grown in DMEM containing 10% FCS were
resuspended in serum-free DMEM and stimulated with 100 .mu.L/well
of HGF (40 ng/mL) plus transforming growth factor-.beta.1 (1 ng/mL,
R&D Systems) to reduce background and various concentrations of
HuL2G7, L2G7 or irrelevant control human antibody. The level of
cell proliferation was determined by the addition of WST-1 (Roche
Applied Science) for 14 hours. FIG. 6 shows that the HuL2G7 and
L2G7 had equal inhibitory activity in this assay. In summary,
HuL2G7 was at least equally as active as L2G7 in all assays used,
and is therefore fully neutralizing: no activity of L2G7 was lost
in the humanization process.
3. Ability of HuL2G7 to Inhibit Tumor Growth In Vivo
[0059] It has already been shown that L2G7 mAb is able to
completely inhibit the growth of U87 glioma xenografts in nude
mouse models (U.S. patent application Ser. No. 10/917,915 filed
Aug. 13, 2004, and Kim et al. Clin Cancer Res 12:1292, 2006). To
verify that HuL2G7 also has this ability, the same experimental
procedure was used. Briefly, female 4-6 week-old NIH III
Xid/Beige/Nude mice (Charles River Laboratories) were injected s.c.
with 10.sup.7 cells in 0.1 ml of PBS in the dorsal areas. When the
tumor size reached .about.50 mm.sup.3, the mice were randomly
divided into groups (n=6 per group) and injected with 40 .mu.g
HuL2G7, L2G7 or control PBS i.p. twice weekly in a volume of 0.1 ml
PBS. Tumor volumes were determined weekly by measuring two
dimensions (length, a, and width, b) and calculating volume as
V=ab.sup.2/2. FIG. 7 shows that HuL2G7 and L2G7 inhibited tumor
growth indistinguishably in this assay. To further define the
ability of HuL2G7 to inhibit growth of tumor xenografts, four
different doses of the mAb, 40 .mu.g, 20 .mu.g, 10 .mu.g and 5
.mu.g, were used in a similar experiment. FIG. 8 shows that even
the remarkably low dose of 10 .mu.g twice weekly was able to
completely inhibit tumor growth, while the even lower dose of 5
.mu.g gave good but incomplete inhibition. Similarly, when
administered systemically HuL2G7 effectively inhibits growth of
intracranial U87 xenographs.
[0060] Although the invention has been described with reference to
the presently preferred embodiments, it should be understood that
various modifications can be made without departing from the
invention.
[0061] All publications, patents and patent applications cited are
herein incorporated by reference in their entirety for all purposes
to the same extent as if each individual publication, patent and
patent application was specifically and individually indicated to
be incorporated by reference in its entirety for all purposes.
[0062] The L2G7 hybridoma has been deposited on Apr. 29, 2003 with
the American Type Culture Collection, P.O. Box 1549 Manassas, Va.
20108, as ATCC Number PTA-5162 under the Budapest Treaty. This
deposit will be maintained at an authorized depository and replaced
in the event of mutation, nonviability or destruction for a period
of at least five years after the most recent request for release of
a sample was received by the depository, for a period of at least
thirty years after the date of the deposit, or during the
enforceable life of the related patent, whichever period is
longest. All restrictions on the availability to the public of
these cell lines will be irrevocably removed upon the issuance of a
patent from the application.
Sequence CWU 1
1
11112DNAArtificial SequenceSynthetic polynucleotide cloning
restriction site 1ctcgagacca cc 122120PRTArtificial
SequenceSynthetic polypeptide for L2G7 mature heavy chain 2Gln Val
Gln Leu Gln Gln Ser Gly Ala Asp Leu Met Lys Pro Gly Ala 1 5 10 15
Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Gly Asn 20
25 30 Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp
Ile 35 40 45 Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asn Tyr Asn
Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser
Ser Asn Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu
Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly His Tyr Tyr
Gly Ser Ser Trp Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr
Val Ser Ser 115 120 3108PRTArtificial SequenceSynthetic polypeptide
for L2G7 mature light chain 3Asn Ile Val Met Thr Gln Ser Pro Lys
Ser Met Ser Met Ser Val Gly 1 5 10 15 Glu Arg Val Thr Leu Thr Cys
Lys Ala Ser Glu Asn Val Val Thr Tyr 20 25 30 Val Ser Trp Tyr Gln
Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala
Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser
Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala 65 70
75 80 Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro
Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100
105 4120PRTArtificial SequenceSynthetic polypeptide for L2G7 heavy
chain mature variable region 4Gln Val Gln Leu Gln Gln Ser Gly Ala
Asp Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys
Ala Thr Gly Tyr Thr Phe Ser Gly Asn 20 25 30 Trp Ile Glu Trp Val
Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile
Leu Pro Gly Ser Gly Asn Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys
Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70
75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr
Cys 85 90 95 Ala Arg Gly Gly His Tyr Tyr Gly Ser Ser Trp Asp Tyr
Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120
5120PRTArtificial SequenceSynthetic polypeptide for HuL2G7 heavy
chain mature variable region 5Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys
Val Ser Gly Tyr Thr Phe Ser Gly Asn 20 25 30 Trp Ile Glu Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile
Leu Pro Gly Ser Gly Asn Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys
Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70
75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95 Ala Arg Gly Gly His Tyr Tyr Gly Ser Ser Trp Asp Tyr
Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
6125PRTArtificial SequenceSynthetic polypeptide for AAC18323 heavy
chain mature variable region 6Gln Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys
Val Ser Gly Tyr Thr Leu Thr Glu Leu 20 25 30 Ser Met His Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Gly Phe
Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 50 55 60 Gln
Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 65 70
75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95 Ala Thr Pro Val Gly Arg Cys Ser Ser Thr Ser Cys Tyr
His Pro Leu 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
Ser Ser 115 120 125 7108PRTArtificial SequenceSynthetic polypeptide
for L2G7 light chain mature variable region 7Asn Ile Val Met Thr
Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly 1 5 10 15 Glu Arg Val
Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr 20 25 30 Val
Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile 35 40
45 Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60 Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val
Gln Ala 65 70 75 80 Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Gly Tyr
Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
Lys Arg 100 105 8108PRTArtificial SequenceSynthetic polypeptide for
HuL2G7 light chain mature variable region 8Asp Ile Val Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr 20 25 30 Val Ser
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Gly Tyr Ser
Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
Arg 100 105 9108PRTArtificial SequenceSynthetic polypeptide for
BAC01726 lighr chain mature variable region 9Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu
Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr
Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys Arg 100 105 10469PRTArtificial SequenceSynthetic polypeptide
for HuL2G7 heavy chain 10Met Asp Cys Thr Trp Arg Ile Leu Phe Leu
Val Ala Ala Ala Thr Gly 1 5 10 15 Thr His Ala Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys
Val Ser Cys Lys Val Ser Gly Tyr Thr Phe 35 40 45 Ser Gly Asn Trp
Ile Glu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 50 55 60 Glu Trp
Ile Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asn Tyr Asn 65 70 75 80
Glu Lys Phe Lys Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Thr Asp 85
90 95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala
Val 100 105 110 Tyr Tyr Cys Ala Arg Gly Gly His Tyr Tyr Gly Ser Ser
Trp Asp Tyr 115 120 125 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys Gly 130 135 140 Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly Gly 145 150 155 160 Thr Ala Ala Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175 Thr Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190 Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 210
215 220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
Lys 225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp Val 275 280 285 Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 305 310 315 320 Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330
335 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
340 345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435 440 445 Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455
460 Leu Ser Pro Gly Lys 465 11234PRTArtificial SequenceSynthetic
polypeptide for HuL2G7 light chain 11Met Glu Ala Pro Ala Gln Leu
Leu Phe Leu Leu Leu Leu Trp Leu Pro 1 5 10 15 Asp Thr His Gly Asp
Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser 20 25 30 Ala Ser Val
Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn 35 40 45 Val
Val Thr Tyr Val Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 50 55
60 Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp
65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser 85 90 95 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
Gly Gln Gly Tyr 100 105 110 Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys Arg 115 120 125 Thr Val Ala Ala Pro Ser Val Phe
Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140 Leu Lys Ser Gly Thr Ala
Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 145 150 155 160 Pro Arg Glu
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175 Gly
Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185
190 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195 200 205 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
Ser Pro 210 215 220 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225
230
* * * * *
References